Cenix Begins Building In Vivo Research Operations, Developing siRNA Delivery Tech
April 30, 2009
Cenix Begins Building In Vivo Research Operations, Developing siRNA Delivery Tech
The company, which until recently has focused almost exclusively "on cell-based work," expects that the delivery technology will facilitate its in vivo work and enable RNAi-based therapeutics.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- RXi Names Inflammatory Disease as Lead Program; Neurological Disease Slips Off Radar
March 26, 2009 / Gene Silencing News - Lorus Therapeutics and Ohio State U Partner on Nanoparticle Delivery of siRNA Cancer Rx
March 25, 2009 / - Traversa Secures $5M in Series B, Nears Close of Research Deals for Delivery Technology
April 2, 2009 / Gene Silencing News - Tekmira Delays Start of Cancer Drug Trial, Sees Expanded Roche Partnership in '09
March 26, 2009 / Gene Silencing News - MDRNA Narrows Pipeline to Focus Exclusively on Liver Cancer, Inks Licensing Deal with Novartis
March 26, 2009 / Gene Silencing News